A. Rivas

发表

Dendritic cells that process and present nominal antigens to naive T lymphocytes are derived from CD2+ precursors.

E. Engleman, J. Kosek, F. Fagnoni, 1997, Journal of immunology.

Alloantigen-specific cytotoxic clones bearing the alpha,beta T cell antigen receptor but not CD4 or CD8 molecules.

E. Engleman, J. Koide, R. Laus, 1990, Journal of immunology.

Cellular and molecular basis of human gamma delta T cell activation. Role of accessory molecules in alloactivation.

E. Engleman, F. Fagnoni, M. Takamizawa, 1995, The Journal of clinical investigation.

Evidence for involvement of the gamma, delta T cell antigen receptor in cytotoxicity mediated by human alloantigen-specific T cell clones.

M. Cleary, E. Engleman, J. Koide, 1989, Journal of immunology.

The VLA-4/VCAM-1 molecules participate in γδ cell interaction with endothelial cells

L. Bermudez, N. Mohagheghpour, A. Rivas, 1992 .

CD4 molecules are associated with the antigen receptor complex on activated but not resting T cells.

E. Engleman, J. Koide, S. Takada, 1988, Journal of immunology.

Natural killer (NK)-like cytotoxic activity of allospecific T cell receptor-gamma,delta+ T cell clones. Distinct receptor-ligand interactions mediate NK-like and allospecific cytotoxicity.

E. Engleman, J. Koide, A. Rivas, 1989, Journal of immunology.

Differential response of CD4+ V7+ and CD4+ V7− T cells to T cell receptor‐dependent signals: CD4+ V7+ T cells are co‐stimulation independent and anti‐V7 antibody blocks the induction of anergy by bacterial superantigen

E. Engleman, C. Ruegg, A. Rivas, 1997, European journal of immunology.

V7 (CD101) ligation inhibits TCR/CD3-induced IL-2 production by blocking Ca2+ flux and nuclear factor of activated T cell nuclear translocation.

E. Engleman, L. Soares, L. Tsavaler, 1998, Journal of immunology.

Translocation Nuclear Factor of Activated T Cell Nuclear Flux and 2 + IL-2 Production by Blocking Ca V 7 ( CD 101 ) Ligation Inhibits TCR / CD 3-Induced

Engleman, L. Soares, L. Tsavaler, 1998 .

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy

Mark M. Davis, Edgar G. Engleman, E. Engleman, 2001, Proceedings of the National Academy of Sciences of the United States of America.

V7, a novel leukocyte surface protein that participates in T cell activation. II. Molecular cloning and characterization of the V7 gene.

E. Engleman, R. Laus, C. Ruegg, 1995, Journal of immunology.

Peptides Derived from the CDR3‐Homologous Domain of the CD4 Molecule Are Specific Inhibitors of HIV‐1 and SIV Infection, Virus‐Induced Cell Fusion, and Postinfection Viral Transmission in Vitro

K. M. Hwang, J. Lifson, M. McGrath, 1990, Annals of the New York Academy of Sciences.

Role of B70/B7-2 in CD4+ T-cell immune responses induced by dendritic cells.

E. Engleman, M. Azuma, F. Fagnoni, 1995, Immunology.

Exosomes as a Tumor Vaccine: Enhancing Potency Through Direct Loading of Antigenic Peptides

P. Paz, L. Zitvogel, J. Le Pecq, 2003, Journal of immunotherapy.

Proliferative response in solid culture of T cells from patients with extrinsic bronchial asthma.

N. Bianco, D. Ponce, A. Rivas, 1986, Immunological investigations.

V7, a novel leukocyte surface protein that participates in T cell activation. I. Tissue distribution and functional studies.

R. Warnke, E. Engleman, C. Benike, 1995, Journal of immunology.

Ligation of the V7 molecule on T cells blocks anergy induction through a CD28-independent mechanism.

E. Engleman, L. Soares, L. Tsavaler, 1997, Journal of immunology.

Cell-mediated effector mechanisms in aging humans.

G. Penchaszadeh, I. Blanca, N. Bianco, 1982, International archives of allergy and applied immunology.